Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy (METIV-HCC)
12 mars 2021 uppdaterad av: Daiichi Sankyo, Inc.
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
The purpose of this study is to determine if tivantinib (ARQ 197) is effective in treating patients with MET diagnostic-high hepatocellular carcinoma (liver cancer) who have already been treated once with another therapy.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Expression of c-Met in tumors correlates with aggressive hepatocellular carcinoma (HCC) features.
Overexpression of the receptor in tumor samples or high level of blood HGF in subjects is related to higher recurrence rate after surgery for HCC, while high c-Met expression correlates with shorter survival in HCC subjects.
In summary, c-Met holds an important prognostic role in the natural history of HCC.
This Phase 3 study in MET Diagnostic-High inoperable HCC subjects has been designed based on the results from the randomized, controlled Phase 2 study conducted by ArQule, Inc. with tivantinib versus placebo in subjects with MET Diagnostic-High inoperable HCC who have failed one prior systemic therapy, mentioned above.
The purpose of this study is to confirm the efficacy of tivantinib in MET Diagnostic-High HCC subjects who were previously treated with one systemic therapy, and to further evaluate the safety profile of the experimental drug in this subject population.
Studietyp
Interventionell
Inskrivning (Faktisk)
383
Fas
- Fas 3
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Pilar, Argentina
-
-
Buenos Aires
-
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
-
-
Caba
-
Buenos Aires, Caba, Argentina
-
-
-
-
New South Wales
-
Camperdown, New South Wales, Australien
-
-
Victoria
-
Heidelberg, Victoria, Australien
-
Melbourne, Victoria, Australien
-
-
Western Australia
-
Nedlands, Western Australia, Australien
-
-
-
-
-
Brussels, Belgien
-
Ghent, Belgien
-
Leuven, Belgien
-
Liege, Belgien
-
-
-
-
-
Barretos, Brasilien
-
Rio de Janeiro, Brasilien
-
-
RS
-
Porto Alegre, RS, Brasilien
-
-
SP
-
Sao Paulo, SP, Brasilien
-
-
-
-
-
Amiens Cedex 1, Frankrike
-
Bordeaux Cedex, Frankrike
-
Caen Cedex 09, Frankrike
-
Clichy, Frankrike
-
Creteil, Frankrike
-
Grenoble, Frankrike
-
Lille Cedex, Frankrike
-
Marseille Cedex 09, Frankrike
-
Montpellier, Frankrike
-
Paris Cedex, Frankrike
-
Paris Cedex 12, Frankrike
-
Reims Cedex, Frankrike
-
Rennes Cedex, Frankrike
-
Toulouse Cedex 09, Frankrike
-
Villejuif Cedex, Frankrike
-
-
-
-
Arizona
-
Tucson, Arizona, Förenta staterna
-
-
California
-
Los Angeles, California, Förenta staterna
-
Orange, California, Förenta staterna
-
-
District of Columbia
-
Washington, District of Columbia, Förenta staterna
-
-
Florida
-
Gainesville, Florida, Förenta staterna
-
-
Illinois
-
Chicago, Illinois, Förenta staterna
-
-
Kansas
-
Westwood, Kansas, Förenta staterna
-
-
Louisiana
-
New Orleans, Louisiana, Förenta staterna
-
-
Maine
-
Scarborough, Maine, Förenta staterna
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna
-
-
Michigan
-
Detroit, Michigan, Förenta staterna
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna
-
-
New Jersey
-
Hackensack, New Jersey, Förenta staterna
-
-
New York
-
New York, New York, Förenta staterna
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna
-
-
South Carolina
-
Charleston, South Carolina, Förenta staterna
-
-
Texas
-
Dallas, Texas, Förenta staterna
-
Galveston, Texas, Förenta staterna
-
Houston, Texas, Förenta staterna
-
-
Washington
-
Seattle, Washington, Förenta staterna
-
-
-
-
-
Benevento, Italien, 82100
-
Bergamo, Italien
-
Bologna, Italien
-
Catania, Italien
-
Firenze, Italien
-
Milano, Italien
-
Modena, Italien
-
Napoli, Italien
-
Padova, Italien
-
Parma, Italien
-
Pavia, Italien
-
Pisa, Italien
-
Reggio Emilia, Italien
-
Roma, Italien
-
Turin, Italien
-
-
Forli-Cesena
-
Meldola, Forli-Cesena, Italien
-
-
Milano
-
Rozzano, Milano, Italien
-
-
Torino
-
Orbassano (TO), Torino, Italien
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Kanada
-
-
Ontario
-
Toronto, Ontario, Kanada
-
-
-
-
-
Amsterdam, Nederländerna
-
-
-
-
-
Auckland, Nya Zeeland
-
-
-
-
-
Lisboa, Portugal
-
Porto, Portugal
-
Vila Real, Portugal
-
-
-
-
-
Bern, Schweiz
-
Zurich, Schweiz
-
-
-
-
-
Alicante, Spanien
-
Barcelona, Spanien
-
Cordoba, Spanien
-
Madrid, Spanien
-
Sabadell, Spanien
-
Santander, Spanien
-
Valencia, Spanien
-
Zaragoza, Spanien
-
-
A Coruña
-
Santiago de Compostela, A Coruña, Spanien
-
-
Asturias
-
Oviedo, Asturias, Spanien
-
-
Madrid
-
Majadahonda, Madrid, Spanien
-
-
Navarra
-
Pamplona, Navarra, Spanien
-
-
-
-
-
Gothenburg, Sverige
-
Stockholm, Sverige
-
-
-
-
-
Aachen, Tyskland
-
Berlin, Tyskland
-
Bonn, Tyskland
-
Duesseldorf, Tyskland
-
Essen, Tyskland
-
Frankfurt am Main, Tyskland
-
Hamburg, Tyskland
-
Hannover, Tyskland
-
Heidelberg, Tyskland
-
Leipzig, Tyskland
-
Magdeburg, Tyskland
-
Mainz, Tyskland
-
Muenchen, Tyskland
-
Munich, Tyskland
-
Regensburg, Tyskland
-
Tuebingen, Tyskland
-
Ulm, Tyskland
-
Wuerzburg, Tyskland
-
-
-
-
-
Graz, Österrike
-
Innsbruck, Österrike
-
Linz, Österrike
-
Wien, Österrike
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Histologically confirmed HCC that is inoperable (where surgery is not indicated due to disease extension, co-morbidities, or other technical reasons), and not eligible for local therapy
- MET Diagnostic-High tissue reported by the central authorized laboratory using archival or recent biopsy tumor samples
- Received at least 4 weeks of one prior sorafenib containing systemic therapy and then experienced documented radiographic disease progression; or inability to tolerate prior therapy received for at least a minimum period of time.
- Discontinued prior systemic treatment or any investigational drug for at least 2 weeks (14 days) or for at least 3 weeks for IV anti-cancer drugs, prior to the study randomization
- Local or loco-regional therapy (i.e., surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) must have been completed >= 4 weeks prior to randomization
- Measurable disease as defined by the RECIST v1.1.
Exclusion Criteria:
- More than 1 prior systemic regimen (prior MET inhibitors/antibodies are not allowed; experimental systemic therapy for inoperable HCC given before or after sorafenib counts as separate regimen and is not allowed)
- Child-Pugh B-C cirrhotic status based on clinical findings and laboratory results
- Previous or concurrent cancer that is distinct from HCC in primary site or histology, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, and superficial bladder tumors. Any cancer curatively treated more than 3 years prior to enrollment is permitted.
- History of congestive heart failure defined as Class II to IV per New York Heart Association (NYHA) classification within 6 months prior to study entry; active coronary artery disease (CAD); clinically significant bradycardia or other uncontrolled, cardiac arrhythmia defined as greater than or equal to Grade 3 according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), or uncontrolled hypertension; myocardial infarction occurring within 6 months prior to study entry (myocardial infarction occurring more than 6 months prior to study entry is permitted)
- Active clinically serious infections defined as >= Grade 3 according to NCI CTCAE
- Any medical, psychological, or social conditions, particularly if unstable, including substance abuse, that may, in the opinion of the Investigator, interfere with the subject's safety or participation in the study, protocol compliance, or evaluation of the study results
- Known human immunodeficiency virus (HIV) infection
- Blood or albumin transfusion within 5 days prior to the blood draw being used to confirm eligibility
- Concomitant interferon therapy or therapies for active Hepatitis C virus (HCV) infection
- Pregnancy or breast-feeding
- History of liver transplant
- Inability to swallow oral medications
- Clinically significant gastrointestinal bleeding occurring <= 4 weeks prior to randomization
- Pleural effusion or clinically evident (visible or palpable) ascites
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Tivantinib 240 mg BID Cohort
The tivantinib dosage of 240 mg tablets administered by mouth twice daily (BID), once in the morning and once in the evening, with food, for a total daily dose of 480 mg.
|
Tivantinib tablets
Andra namn:
|
|
Experimentell: Tivantinib 120 mg BID Cohort
Tivantinib 120 mg is administered by oral tablet BID, once in the morning and once in the evening, with food, for a total daily dose of 240 mg (amended dosing group; primary analysis group).
|
Tivantinib tablets
Andra namn:
|
|
Placebo-jämförare: Placebo Matching 240 mg BID Cohort
Matching placebo is administered by oral tablet(s) BID, once in the morning and once in the evening, with food.
|
Matchande placebotabletter
Andra namn:
|
|
Placebo-jämförare: Placebo Matching 120 mg BID Cohort
Matching placebo is administered by oral tablet(s) BID, once in the morning and once in the evening, with food.
|
Matchande placebotabletter
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Median Overall Survival (OS) Following Treatment With Tivantinib 120 mg BID Compared to Placebo Group in Participants With MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Systemic Therapy
Tidsram: within 36 months
|
Overall survival (OS) is defined as the time from randomization to the date of death.
The rate of OS (percentage of participants still alive) was determined only in the tivantinib 120 mg BID cohort.
|
within 36 months
|
|
Overall Survival (OS) Rate At Different Time Points Following Treatment With Tivantinib 120 mg BID Compared to Placebo Group in Participants With MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Systemic Therapy
Tidsram: within 36 months
|
Overall survival (OS) is defined as the time from randomization to the date of death.
The rate of OS (percentage of participants still alive) was determined only in the tivantinib 120 mg BID cohort.
|
within 36 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Progression-free Survival Following Treatment With Tivantinib 120 mg BID Compared to Placebo Group in Participants With MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Systemic Therapy (ITT Population)
Tidsram: within 10 months
|
Progression-free survival (PFS) is defined as the time from the date of randomization to the date of the first radiographic disease progression or death due to any cause.
The rate of PFS (percentage of participants still alive without disease progression) was determined only in the tivantinib 120 mg BID cohort.
|
within 10 months
|
|
Treatment-Emergent Adverse Events Reported (>20% in Tivantinib Cohort) Following Treatment With Tivantinib Compared With Placebo in Participants With MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Systemic Therapy
Tidsram: Baseline to 30 days after last dose, up to approximately 4 years
|
Treatment-emergent adverse events (TEAEs) are reported for the tivantinib 120 mg BID cohort group.
|
Baseline to 30 days after last dose, up to approximately 4 years
|
|
Treatment-Emergent Adverse Events Reported (>20% in Tivantinib Cohort) Following Treatment With Tivantinib Compared With Placebo in Participants With MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Systemic Therapy
Tidsram: Baseline to 30 days after last dose, up to approximately 4 years
|
Treatment-emergent adverse events (TEAEs) are reported for the tivantinib 240 mg BID cohort group.
|
Baseline to 30 days after last dose, up to approximately 4 years
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
27 december 2012
Primärt slutförande (Faktisk)
28 mars 2017
Avslutad studie (Faktisk)
31 juli 2017
Studieregistreringsdatum
Först inskickad
19 december 2012
Först inskickad som uppfyllde QC-kriterierna
19 december 2012
Första postat (Uppskatta)
24 december 2012
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
6 april 2021
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
12 mars 2021
Senast verifierad
1 mars 2021
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- ARQ197-A-U303
- 2012-003308-10 (EudraCT-nummer)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .